Picture of Aptorum logo

APM Aptorum Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+0.34%
3m+1.12%
6m-11.63%
1yr-59.9%
Volume Change (%)
10d/3m+45.44%
Price vs... (%)
52w High-79.22%
50d MA-1.98%
200d MA-17.91%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-120.17%
Return on Equity-60.24%
Operating Margin-1299.91%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Aptorum EPS forecast chart

Profile Summary

Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Company’s lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
January 1st, 1970
Public Since
December 18th, 2018
No. of Shareholders
27
No. of Employees
18
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
5,181,697
Blurred out image of a map
Address
17 Hanover Square, LONDON, W1S 1BN
Web
http://www.aptorumgroup.com/
Phone
+44 2080929299
Auditors
Marcum Bernstein & Pinchuk LLP

APM Share Price Performance

Upcoming Events for APM

Full Year 2023 Aptorum Group Ltd Earnings Release

Similar to APM

Picture of 60 Degrees Pharmaceuticals logo

60 Degrees Pharmaceuticals

us flag iconNASDAQ Capital Market

Picture of Aadi Bioscience logo

Aadi Bioscience

us flag iconNASDAQ Capital Market

Picture of Acasti Pharma logo

Acasti Pharma

us flag iconNASDAQ Capital Market

Picture of Affinia Therapeutics logo

Affinia Therapeutics

us flag iconNASDAQ Capital Market

Picture of Agriforce Growing Systems logo

Agriforce Growing Systems

us flag iconNASDAQ Capital Market

FAQ